Home » Topics » Disease categories and therapies » Cardiovascular

Cardiovascular
RSS

Cypros to start phase III trial for CABG

Oct. 3, 1997

Focus on benzoyl guanidines as Na+/H+-exchange inhibitors

Oct. 2, 1997

Cytel reports encouraging results from Cylexin phase I/II trial

Oct. 2, 1997

Single- and multiple-dose clinical studies reported for SL-91.0102

Oct. 1, 1997

New treatment for ISH evaluated in humans

Oct. 1, 1997

Na+/K+-exchange inhibitors from Fujisawa

Sep. 30, 1997

Clinical pharmacokinetics and bradycardic activity of S-16257

Sep. 30, 1997

Mechanism of action revealed for Theratechnologies' Protectazem

Sep. 29, 1997

Endothelin agonists/antagonists from Texas Biotechnology

Sep. 29, 1997

New Na+/H+-exchange inhibitors from Fujisawa

Sep. 26, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Kymera’s IRF5 degrader shows potential in IBD treatment
BioWorld Science
At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...